BACKGROUND: An accurate diagnosis of cancer of M€ ullerian origin is required before the initiation of treatment. An overlap in clinical presentation and cytological, histological, or imaging studies with other nongynecological tumors does occur. Therefore, immunocytochemistry markers are used to determine tumor origin. Human epididymis protein 4 (HE4)
INTRODUCTION
An accurate initial diagnosis of cancer of M€ ullerian origin is necessary for tumor staging and the determination of an optimal treatment strategy. The majority of patients with M€ ullerian cancer present with nonspecific abdominal symptoms and therefore are not diagnosed until the disease has extended to the upper abdomen or spread beyond the abdominal cavity. 1, 2 The high mortality rate of patients with M€ ullerian cancer is a consequence of this late manifestation of the disease. In individuals with advanced stage disease, M€ ullerian cancer metastasizes to the abdominal cavity and causes malignant peritoneal and/or pleural effusions. Patients with serous ovarian, tubal, and peritoneal malignancies have a similar presentation and prognosis. Independent of this origin, patients are treated in the same way. These tumors often are referred to as M€ ullerian tumors based on their shared embryologic origin from the M€ ullerian ducts. Performing a paracentesis of ascites to obtain a sample for diagnosis is a common and easy procedure. Immunohistochemistry (IHC) or immunocytochemical analysis is helpful in the differential diagnosis between mesothelial cells and a variety of tumor types, and often involves the use of a panel of antibodies instead of individual markers 3 : Ber-Ep4 (usually for adenocarcinomas and cancers of the glandular epithelium), Wilms tumor gene 1 (WT1) (for high-grade serous adenocarcinoma and that of the mesothelium), estrogen receptor (ER) (for gynecological and breast cancers), cytokeratin (CK) 7 (for gynecological, upper gastrointestinal, lung, and mesothelial cell), CK20 (for lower gastrointestinal and mucinous adenocarcinoma), and caudal type homeobox 2 (CDX2) (for lower and upper gastrointestinal, mucinous adenocarcinoma). 4, 5 Other IHC markers that are commonly used are cancer antigen 125 (CA125), which mainly identifies epithelium of gynecological origin, and carcinoembryonic antigen (CEA), which mainly identifies epithelium of gastrointestinal origin. However, both are too nonspecific for an accurate diagnosis as a single marker. A relatively new marker is paired box 8 (PAX8), a member of the pair box family of tissue-specific transcription factor genes. Expression of PAX8 is present in the female genital tract derived from the M€ ullerian ducts. 6 This supports the recent belief that epithelial ovarian cancer (EOC) originates from the fallopian tubes instead of from the surface epithelium of the ovary. 7 PAX8 can be used to distinguish gynecologic cancers from non-M€ ullerian malignancies, including cancers of gastrointestinal origin and from mesothelial cells. 8, 9 Recently, human epididymis protein 4 (HE4) was found to be overexpressed in EOC tissue. 10 The gene encoding for HE4, WFDC2, is located on chromosome 20q12-13. 11 In normal human tissue, HE4 expression is limited to the epithelia of the (uro) genital and respiratory tract in both men and women. 12, 13 In addition to EOC, some endometrial carcinomas, breast cancers, and pulmonary adenocarcinomas have demonstrated HE4 expression.
Adenocarcinomas of the gastrointestinal tract demonstrate HE4 expression less often. 13 Over the last few years, HE4
has developed into a relatively specific and sensitive serum marker for EOC. 14, 15 To the best of our knowledge, HE4 has not been evaluated in ascites to date. Therefore, we investigated whether immunostaining with HE4 in ascites is feasible and could facilitate the differentiation between EOC and adenocarcinomas of gastrointestinal origin.
MATERIALS AND METHODS

Collection of Samples and Data
Paraffin-embedded cell blocks of ascites specimens from patients with cancers of M€ ullerian origin or with gastric or colorectal cancer were obtained from the biobank of the Netherlands Cancer Institute (NKI-AVL) after approval of the Institutional Review Board. In the case of gastric and colorectal cancers, both men and women were included. Relevant clinical data were collected for all patients and the definitive histological diagnosis, tumor subtype, and primary origin of the M€ ullerian cancers (ovary, fallopian tube, or peritoneum) were obtained from the pathology reports. In case of doubt, a review of the original Giemsastained and hematoxylin and eosin-stained slides was performed by a dedicated gynecologic pathologist (K.K.V.).
Serous adenocarcinomas were divided into low grade and high grade, whereas mucinous adenocarcinomas were divided into low, moderately, or highly differentiated. All specimens were handled in a coded fashion as prescribed by the Dutch national guidelines for the secondary use of specimens.
Immunohistochemistry
PAX8 and HE4 staining were performed on all slides. In addition, staining of at least 2 other markers was performed: 1 marker from a panel composed of WT1, ER, and CK7 and 1 marker from a panel composed of CK20, CEA, and CDX2. HE4 antibody was kindly provided by Fujirebio Diagnostics Inc. Formalin-fixed and paraffinembedded tissue slides of EOC resection specimens were used for testing and as controls. IHC of samples was performed on a BenchMark ULTRA autostainer (Ventana Medical Systems, Tucson, Ariz). Briefly, paraffin sections were cut at 3 lm, heated at 75 8C for 28 minutes, and deparaffinized in the instrument with EZ Prep solution (Ventana Medical Systems). Heat-induced antigen retrieval
Original Article was performed using Cell Conditioning 1 (CC1; Ventana Medical Systems) for 32 minutes at 95 8C (for WT1, CK20, CK7, CA 125, CEA, and CDX2) or 64 minutes at 95 8C (for PAX8 and HE4).
WT1 was detected using clone 6F-H2 (1:50 dilution, 32 minutes at 37 8C; Dako, Carpinteria, Calif), CK20 was detected using a polyclonal antibody (1:6000 dilution, 32 minutes at 37 8C; ImmunoLogic, Duiven, the Netherlands [category E16444]), PAX8 was detected using clone MRQ-50 (1:100 dilution, 32 minutes at 37 8C; Sanbio Laboratory, Boerne, Tex), HE4 was detected using clone 12A2 (1:2000 dilution, 32 minutes at 36 8C; Fujiribo Diagnostics Inc, Malvern, Pa), CK7 was detected using clone OVTL12/30 (1:200 dilution, 32 minutes at 37 8C; Monosan, Uden, the Netherlands), CA 125 was detected using clone Ov185:1 (1:40 dilution, 32 minutes at 37 8C; BioGenex, Fremont, Calif), CEA was detected using clone Col-1 (1:200 dilution, 32 minutes at 37 8C; GeneTex Inc, Irvine, Calif), and CDX2 was detected using clone EPR2764Y (1:1600 dilution, 32 minutes at 37 8C; Thermo Fisher Scientific, Waltham, Mass). For PAX8 and HE4, an additional amplification step (Ventana Medical Systems) was selected in the protocol to amplify this primary antibody, using the OptiView Amplification Kit (Ventana Medical Systems). Bound antibody was detected using the OptiView DAB Detection Kit (Ventana Medical Systems). Slides were counterstained with hematoxylin II and Bluing Reagent (Ventana Medical Systems).
Evaluation of Immunocytochemistry Staining
Evaluation of the slides was performed by 2 observers (A.S. and K.K.V.) without previous knowledge of the clinical characteristics and the histology report. HE4, PAX8, WT1, ER, and CDX2 have a nuclear staining pattern, whereas CK7, CK20, and CEA have a cytoplasmic staining pattern. The percentage of tumor cells staining for HE4 was based on review of the entire cytological section of the cell block. Slides with an extremely low quantity of tumor cells were excluded from the current study. Slides with tumor cells that demonstrated HE4 staining were further scored as "strong," "moderate," or "weak." Weak staining in < 5% of tumor cells was considered as no staining in the final results. The same definitions were applied to the other immunocytochemistry markers (PAX8, WT1, CK7, CK20, ER, CA 125, CEA, and CDX2).
Statistical Analysis
A Fisher exact test was used to compare the amount of positive HE4 staining between men and women in the group of gastrointestinal cancer cases. 
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RESULTS
A total of 123 cell blocks of ascites were collected and stained. After staining, 8 cases were excluded because of the absence of tumor cells (5 cases) or a definitive histological diagnosis (3 cases). Of the remaining 115 specimens, there were 45 samples from patients with M€ ullerian cancer (all 45 were of primary ovarian origin), 46 from patients with gastric cancer, and 24 from patients with colorectal cancer. The slides were reviewed based on the diagnostic criteria described above. The group of EOC cases consisted mainly of high-grade serous adenocarcinomas (37 cases; 82%). The most common histological subtype in the gastric cancer group was diffuse-type adenocarcinoma (38 cases; 83%), and the remaining subtypes were intestinal-type adenocarcinoma (5 cases; 11%), mixed diffuse-/intestinal-type adenocarcinoma (2 cases; 4%), or mucinous adenocarcinoma (1 case; 2%). The histological subtypes of colon cancer were intestinal-type adenocarcinoma (8 cases; 33%); adenocarcinoma, not otherwise specified (9 cases; 38%); mucinous-type adenocarcinoma (1 case; 4%); and mixed adenocarcinomas (3 cases; 13%). Of the remaining 3 tumors, a histological diagnosis could not be confirmed because tumor tissue from the surgical resection specimen was not available for pathology review.
HE4 Staining
Results of HE4 staining are summarized in Table 1 . A nuclear staining pattern was observed for HE4. Ascites from EOC stained positively for HE4 in 91% of cases (41 cases) (Figs. 1A and 1B) and strong HE4 staining was observed in 50% of tumor cells. All high-grade serous adenocarcinoma cases (37 cases) were found to stain positively for HE4. The 4 specimens that did not demonstrate HE4 staining were a low-grade serous adenocarcinoma, a clear cell adenocarcinoma, an undifferentiated adenocarcinoma, and a neuroendocrine carcinoma (Fig. 1C) . A mucinous adenocarcinoma stained positively for HE4 as well.
The ascites samples from patients with gastric cancer stained positively for HE4 in 24% of cases (11 cases) ( Fig. 2A) . Among these were 9 diffuse-type adenocarcinoma cases, 1 intestinal-type adenocarcinoma case, and 1 mucinous-type adenocarcinoma case. Among the 24 colorectal cancer specimens, HE4 immunostaining was observed in only 5 cases (21%): 2 intestinal-type adenocarcinomas; 1 mucinous adenocarcinoma; 1 mixed intestinal-/mucinous-type adenocarcinoma; and 1 adenocarcinoma, not otherwise specified. In the remaining 19 specimens (79%), HE4 immunostaining was negative (Fig. 2B) . Strong HE4 staining in gastrointestinal cancer specimens was observed in 9 of 16 positive cases (56%) and the remaining 7 specimens (44%) demonstrated moderate HE4 staining. In total, the group of patients with gastrointestinal carcinomas consisted of 37 men and 33 women. Among men, positive HE4 staining was observed in 10 specimens (27%) compared with 6 cases in women (18%) (P 5 .28). We did not observe HE4 staining in any benign cellular elements as mesothelial cells of Blymphocytes.
PAX8 Staining
Strong nuclear PAX8 immunostaining was observed in 91% of ascites (41 ascites cases) from patients with EOC and in none of the ascites samples from patients with gastrointestinal cancer ( Table 2 ). 94% of high-grade serous adenocarcinoma cases stained positively for PAX8. Ascites from a clear cell carcinoma also demonstrated strong PAX8 staining. The 4 EOC specimens that did not demonstrate PAX8 immunostaining were 2 high-grade serous adenocarcinomas, a mucinous adenocarcinoma, and a neuroendocrine carcinoma. It is interesting to note that lymphocytic cells also demonstrated diffuse PAX8 staining in 19 of the total of 115 specimens (17%).
Combinations of Markers
WT1
, ER, and CDX2 demonstrated nuclear staining, whereas CK7, CK20, and CEA were found to have a cytoplasmic staining pattern. The number of specimens that stained for any of these markers is presented in Table 2 .
Absence of HE4 and PAX8 staining was observed in 1 neuroendocrine carcinoma (2%). This specimen only demonstrated positive CK7 staining. In 3 of 45 EOC specimens (7%), none of the 3 markers (WT1, ER, or CK7) demonstrated positive staining (Table 2) . These specimens were composed of 3 high-grade serous adenocarcinomas with positive HE4 and PAX8 staining.
The sensitivity and specificity of HE4 and PAX8 and a combination of markers are listed in Table 2 . The combination of HE4 and PAX8 staining was found to have a sensitivity of 84% and a specificity of 100% for the differential diagnosis between EOC and gastrointestinal carcinomas. Combinations with other markers from the gynecological panel did not appear to improve the sensitivity or specificity further (sensitivity of 93% and specificity of 80%).
DISCUSSION
In the current study, we examined the use of HE4 as an immunostaining marker in ascites from patients with EOC and patients with adenocarcinomas of gastrointestinal origin and compared this with PAX8 and other well-known IHC markers. The results demonstrated that HE4 staining was strongly present (91%) in the ascites of patients with EOC in contrast with HE4 staining in the ascites of patients with gastric and colorectal cancers. Furthermore, 100% of the high-grade serous adenocarcinomas of the ovary stained positively for HE4 compared with 94% for PAX8. The sensitivity to differentiate between ascites from EOC and ascites from gastrointestinal cancer was comparable for HE4 and PAX8, whereas the specificity of HE4 for the total group of samples was lower. Other markers performed less well and could be replaced by HE4. As a single marker, HE4 does not appear to be better than PAX8, but when used in combination it could be enough in cases in which a (high-grade) serous adenocarcinoma is suspected. The number of markers that are used in a panel could thereby be reduced.
The abdominal cavity is the primary site of metastatic disease in patients with M€ ullerian cancer and this often results in the presence of ascites. Patients with metastasized gastrointestinal malignancies and other malignancies such as breast cancer also can present with generalized peritonitis with corresponding ascites. The initial diagnosis of M€ ullerian cancer often is based on cytology (72%) compared with histology (17%) or clinical factors alone (10%). 16 Confirming the M€ ullerian origin of metastatic disease in ascites specimens can be difficult based on cell morphology only. The use of immunostaining markers contributes to the accuracy of the correct diagnosis of intra-abdominal malignancies before the onset of treatment. The clinical implications of a misdiagnosis vary and depend on the origin of the primary tumor but may have serious consequences (eg, a patient with a gastrointestinal tumor will be considered for different chemotherapy regimens and for cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy). This highlights the importance of the evaluation of new immunocytochemistry markers that can be used to differentiate between M€ ullerian cancer and non-M€ ullerian adenocarcinomas. Currently, several markers (WT1, CK7, CK20, ER, CA 125, CEA, and CDX2) are often used for immunostaining in addition to morphologic features. Recently, PAX8 has been added to this panel of IHC markers. Different results have been reported with PAX8, but overall the sensitivity is high (85%-100%). 6, 9 In the study by
Zhao et al, an overall detection rate of 85% was found. Subgroup analysis demonstrated a sensitivity of 85% in serous subtypes (52 cases) and 100% in a small subgroup (5 cases) of clear cell carcinomas of the ovary. 9 We reported a similar sensitivity for PAX8 and HE4 of 91% for each. However, in a subgroup of high-grade serous adenocarcinomas only, HE4 staining was found to be positive in 100% of cases compared with 94% for PAX8. A combination of HE4 and PAX8 could increase the specificity to 100%. It is interesting to note that we observed some staining with WT1 and PAX8 in the reactive cells, which also has been observed by others. 6, 9 This can be confusing when mesothelial cells or large B-lymphocytic cells have to be distinguished from cancer cells, and therefore highlights the importance of using IHC markers in panels and not separately. The small numbers of some of the histological subtypes that were included in the current study limit the possibility of drawing a definitive conclusion regarding HE4 expression in EOC other than serous subtypes. Furthermore, we limited the current study to the evaluation of ascites of patients with EOC and adenocarcinomas of gastrointestinal origin and did not include other malignancies that can present with peritonitis and ascites (eg, pancreatic carcinoma and breast cancer). A previous study in which immunostaining was performed on tissue slides of different tumor types demonstrated variable HE4 staining in breast tumors and staining in the majority of pancreatic tumors, but no staining in gastrointestinal tumors. 13 This suggests that for the differentiation between tumor types, immunostaining with HE4 cannot be used alone but should be used in combination with other markers such as PAX8.
The most common histological subtype in the gastric cancer group included herein was diffuse-type adenocarcinoma. This is expected because diffuse-type adenocarcinomas of gastric origin tend to metastasize to the peritoneal cavity and cause ascites more often than intestinal-type gastric carcinomas. 17 Serum HE4 was not available for all patients because it is not a standard diagnostic tool for gastrointestinal tumors. Therefore, we could not correlate serum concentrations with immunostaining results. However, we have shown in a previous study that serum HE4 can be used for the differentiation between EOC and ovarian metastases of gastrointestinal origin. 18 A combination of these 2 diagnostic possibilities, serum HE4 and HE4 immunostaining, could improve the differentiation of EOC from other adenocarcinomas with or without ovarian metastases. Despite the previously mentioned limitations, to the best of our knowledge the current study is the first to evaluate immunostaining with HE4 in the ascites of patients with EOC and patients with gastrointestinal cancer. HE4 staining is feasible in ascites and is a useful addition to the current panel of immunocytochemistry markers for the diagnosis of high-grade serous ovarian cancer and for the differentiation with gastrointestinal-derived adenocarcinomas.
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